Trials
1 active
3 in total · 2 in the EU
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Intranasal administration of multiple ascending doses of CHF6467 in 3 different cohorts”In the company’s words, NCT07163182 on ClinicalTrials.gov
- Main trialPhase 1
- “A clinical trial to investigate the safety and tolerability of single and multiple intranasal (through the nose) dosing with the study drug CHF6467 in 68 healthy adult subjects. The study will investigate also how CHF6467 moves and behaves in the blood and in the fluid around the brain and spinal cord (cerebrospinal fluid) and if the drug CHF6467 causes an immune response by looking for specific molecules, called antibodies that may form against it. The study will be divided into two parts - Part 1 (testing single ascending doses of the study drug, SAD, lasting 4 days) and Part 2 (testing…”In the company’s words, NCT07163182 on ClinicalTrials.gov
Coming up1
- 28 Feb 2027Phase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Recruiting | 28 Feb 2027 | Evaluation of Safety, Side Effects and How the Drug CHF6467 Administered Via Intranasal Route is Absorbed, Modified and Removed in Healthy Subjects | |
| Phase 1/2Completed | 7 Jan 2021 | CHF6467 SAD and MAD in Patients With Diabetic Foot Ulcer | |
| Phase 1/2Ended | not given | Safety and Efficacy of multiple doses of the PAINLESS Nerve Growth Factor CHF6467 in paediatric subjects with Optic Pathway Glioma (OPG). A randomized clinical trial (RCT) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026